accountvia COMTEX/ -- Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, today announces its partner Allergan, Inc has initiated two Phase II trials to evaluate the safety and efficacy of its re-targeted...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Syntaxin Announces its Partner Allergan Enters Phase II Trials With Re-Targeted Endopeptidase Drug
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account